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Available online xxxxRecent results imply that rare variants contribute to the risk of schizophrenia. Exome sequence data from the
UK10K project was used to identify three rare, amino acid changing variants in the ITGB4 genewhich segregated
with schizophrenia in two families: rs750367954, rs147480547 and rs145976111. Association analysis was car-
ried out in the exome-sequenced Swedish schizophrenia study and in UCL schizophrenia and bipolar cases and
controls genotyped for these variants. A gene-wise weighted burden test was performed on a trio sample of
schizophrenia cases and their parents. rs750367954 was seen in two Swedish cases and in no controls. The
other two variantswere commoner in cases than controls in both Swedish andUCL cohort samples and anoverall
burden test was signiﬁcant at p = 0.0000031. The variants were not observed in the trio sample but ITGB4 was
most highly ranked out of 14,960 autosomal genes in a gene-wise weighted burden test. The effect of
rs147480547 and rs145976111 was studied in human neuroblastoma SH-SY5Y cells. Cells transfected with
both variants had increased proliferation at both 24 and 48 h (p = 0.013 and p = 0.05 respectively) compared
to thosewithwild-type ITGB4. Taken together, these results suggest that rare variants in ITGB4which affect func-
tion may contribute to the aetiology of schizophrenia and bipolar disorder.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Genetic risk1. Introduction
The results of exome sequence studies imply a role for rare variants
in the aetiology of schizophrenia (SCZ).Most studies to date have impli-
cated pathways and sets of genes rather than individual genes (Curtis
and UK10K Consortium, 2016; Genovese et al., 2016; Purcell et al.,
2014; Singh et al., 2017), however, a combined analysis of case control
and trio sequence data has implicated rare loss of function variants in
the SETD1A gene (p = 3.3 × 10−9) in the aetiology of SCZ (Singh et al.,
2016).
Analysis of sequencing data from multiply affected extended pedi-
grees can be valuable for identifying extremely rare variants that are
transmitted to affected individuals (Curtis, 2011) and this approach
has been successful in identifying variants in the PLD3 (phospholipaseolecular Psychiatry Laboratory,
K.
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versity College London, London,
. This is an open access article under
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d bipolar disorder..., SchizophD3) gene in late-onset Alzheimer's disease (Cruchaga et al., 2014). Re-
cently a whole genome-sequencing study identiﬁed two different rare,
protein-truncating variants in the RBM12 gene cosegregating with psy-
chosis in two different pedigrees (Steinberg et al., 2017). Herewe report
the discovery and follow-up of rare, protein-changing variants which
were observed to cosegegrate with SCZ in subjects from two multiply-
affected families which were sequenced as part of the UK10K project
(Muddyman et al., 2013; UK10K Consortium et al., 2015).
2. Material and methods
2.1. Subjects
Four independent datasets were used. These comprised:
2.1.1. UK10K cohort
We used British subjects from the UK10K dataset comprising 1392
with SCZ and 982 with severe childhood obesity (SCOOP) not known
to have mental illness which have been described elsewhere (Curtis
and UK10K Consortium, 2016). UK10K subjects were exome sequenced
with coverage of 72× as described in full elsewhere (UK10KConsortiumthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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published and unpublished families multiply affected with SCZ that
had been collected at UCL (Kalsi et al., 1994; Sherrington et al., 1988).
Exome data was available for between 2 and 5 affected members per
pedigree.
2.1.2. Swedish SCZ study
The Swedish SCZ study consisted of the 2545 controls and 2545
cases with SCZ from Sweden for whom whole exome sequence data is
available via dbGaP (Purcell et al., 2014). Detailed sample descriptions
have been provided previously (Purcell et al., 2014).
2.1.3. Bulgarian trio sample
The Bulgarian trio sample consisted of probands with SCZ and their
parents (Fromer et al., 2014; Rees et al., 2015). The sample comprised
whole exome sequence data from 591 trios, consisting of probands
with SCZ and their parents, ﬁve of whom were also affected (Fromer
et al., 2014; Rees et al., 2015). The short read ﬁles were downloaded
from dbGaP along with family structure and phenotype information.
2.1.4. UCL case-control samples
The UCL case-control samples sample and the recruitment methods
have been previously described (Al Eissa et al., 2017; Fiorentino et al.,
2014). Brieﬂy, the sample comprised 1917 bipolar disorder (BP)Fig. 1. Non-synonymous ITGΒ4 variants in two families multiply affected by schizophrenia and
suffering from schizophrenia; shaded shapes represent other psychiatric diagnoses as indicate
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cruited from the UK.2.2. Variant selection and bioinformatic prediction of variant impact
Custom-written software was used to annotate and identify rare,
possibly functional variants shared between affected pedigrees mem-
bers in theUCL samples included inUK10K. The impact of these variants
was predicted using the PolyPhen-2 (Adzhubei et al., 2013) and Sort In-
tolerant from Tolerant (SIFT)(Kumar et al., 2009) bioinformatics tools.2.3. Sanger sequencing in families F047 and F158
Exome sequence data was available for three members of family
F158 (subjects 3, 5 and 7) and for twomembers of family F047 (subjects
3 and 5; Fig. 1) from the UK10K sample. Transmission of rs750367954
(allele T) in family F158 and of rs147480547 (allele A) and
rs145976111 (allele T) in family F047was sought in all additional family
members with available DNA by PCR and Sanger sequencing (Fig. 1).
There was a limited amount of DNA available for individual 4 from fam-
ily F047 and it was not possible to verify the genotype status of
rs147480547 in this individual (Fig. 1).other psychopathology. unk Genotype not determined; ﬁlled shapes represent individuals
d.
ly affected families, association studies and functional analysis suggest
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Non-synonymous variants segregatingwith SCZ in families F047 and
F158 were selected for genotyping in the SCZ, BP and control samples.
Genotyping was performed in-house with allele-speciﬁc PCR using
KASPar reagents (LGC Genomics, Hoddesdon, UK) on a LightCycler
480 (Roche, Burgess Hill, UK) real-time PCR machine. Allele-speciﬁc
primers were designed for each of the SNPs using Primer Picker (LGC
Genomics) as shown in Supplementary Table 1. Genotyping of each het-
erozygote sample was repeated at least twice and known heterozygote
individuals were included on each genotyping plate to ensure reliable
calling of heterozygote subjects.
2.5. Variant calling in trios
The short read ﬁles from the Bulgarian trio sample were converted
to fastq ﬁles using the fastq-dump utility of the dbGaP SRA toolkit.
Reads were then aligned to the hg19 human reference sequence
(build GRCh37) using Novoalign V3.02.08 (NovoCraft Technologies),
duplicate reads were marked using SAMBLASTER (Faust and Hall,
2014) and the BAM ﬁles were sorted using Novosort V1.03.09
(NovoCraft Technologies). Genotypes were called according to GATK
best practices (Broad Institute). The HaplotypeCaller module of GATK
V3.6 was used to produce gVCF ﬁles and these were then combined
using the CombineGVCFs module. Initial calls were made using the
GenotypeGVCFsmodule and then SNPs were ﬁltered based on accuracy
estimates produced by VariantRecalibrator and indels were ﬁltered
using the VariantFiltration module and the ﬁltering expression “QD
b 2.0 || FS N 50.0 || ReadPosRankSum b−20.0”.
2.6. Statistical analysis
2.6.1. Case-control analysis
Allelic association analyses for the genotyped SNPs were performed
using Fisher's exact test in the Swedish and UCL samples separately and
in combination with each other. A burden test was performed by com-
bining information from all genotyped SNPs to compare the total vari-
ant allele counts between cases and controls. Statistical analyses were
performed using R (R Core Team, 2017).
2.6.2. Weighted burden analysis of whole exome sequence data from
schizophrenia trios
The exome-sequenced trios were used to perform a gene-wise
weighted burden analysis across all autosomal genes. Genotypes of au-
tosomal variants in each gene were exported to SCOREASSOC (Curtis,
2012; Curtis and UK10K Consortium, 2016), which was used to con-
struct a sample of pseudo-controls with genotypes consisting of the
untransmitted alleles from the parents of each affected proband. A num-
ber of QCmeasureswere applied. Variantswere excluded if they did not
have a PASS in the information ﬁeld and individual genotype calls were
excluded if they had a genotype quality score b 60. Variants were also
excluded if N10% of cases or of pseudo-controls failed this quality
threshold or if the heterozygote count was smaller than both homozy-
gote counts in both cohorts. Indel calls seemed to produce artefactual
results so were excluded. SCOREASSOC was used to carry out gene-
wise weighted burden tests as previously described (Curtis, 2012;
Curtis and UK10K Consortium, 2016) on the 591 pairs of cases and
pseudo-controls to test whether there was an excess of rare, functional
variants among cases. Only variants with a frequency of b0.01 in cases
or pseudo-controls were considered. Functional weights were assigned
so that variant types deemed more likely to have a functional effect
were assigned higher weights in an approach similar to that recently
suggested for dealing with de novomutations (Jiang et al., 2015). Stop
gain mutations were allocated a weight of 20. Non-synonymous vari-
ants were assigned a weight of 10. Stop loss and splice site variants
are assigned a weight of 5. Other variants were not considered. ToPlease cite this article as: O'Brien, N.L., et al., Rare variant analysis inmultip
a role for the ITGΒ4 gene in schizophrenia and bipolar disorder..., Schizophcarry out a weighted burden analysis a score was calculated for each
subject consisting of the sum of theweights of the variant alleles carried
by that subject. A gene-wise test for association was then performed
using a t-test to see if the average scores for the cases were higher
than for the pseudo-controls, indicating that the cases tend to have an
excess of rare, functional variants. The result of this weighted burden
test was summarised as a signed log p (SLP), which is the logarithm
base 10 of the two-tailed p value, given a positive sign if the mean
score is higher for cases than pseudo-controls.
2.7. Cell lines
Undifferentiated SH-SY5Y human neuroblastoma cell lines were ob-
tained from Sigma Aldrich (Gillingham, UK). The cells were cultured as
mono layers in DMEM (Dulbecco's Modiﬁed Eagle Media), 10% FBS
(Fetal Bovine Serum), 1% Penicillin (50 U/ml)/Streptomycin (50 μg/
ml) maintained at 37 °C and 5% CO2. Cells were not passaged beyond
passage 25.
2.8. ITGB4 plasmid constructs
A TrueORF gold ITGB4 plasmid with a c-terminal Myc-DDK tag was
obtained from Origene (RC220541, Origene Technologies, Rockville,
MD, USA). The ITGB4 genetic variants rs147480547 allele A and
rs145976111 allele T were introduced into the plasmid using the Q5®
Site-Directed Mutagenesis Kit (New England Biolabs) and following
the manufacturer's protocol. A plasmid containing both of the genetic
variants was also constructed using the Q5® Site-Directed Mutagenesis
Kit (New England Biolabs, UK).
2.9. Cell transfections
SH-SY5Y cells were transfected using lipofectamine 2000 (Life tech-
nologies, UK). Growthmedia was removed and cells were washed with
PBS. Growthmedia was then replacedwith Opti-MEM® reducedmedia
serum (Life technologies, UK). Cell samples were transfected with four
different DNA plasmid constructs, wildtype ITGB4, ITGB4 rs147480547
allele A, ITGB4 rs145976111 allele T and a plasmid construct containing
both variants in the ITGB4 cDNA. Successful transfection was deter-
mined using quantitative RT-PCR (not shown).
2.10. Cell proliferation assay
Cells were seeded at a density of 1x105cells/cm2 and incubated for
24 and 48 h after transfection before cell proliferation was assayed.
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazoliumbromide)
was used to measure cellular proliferation (Sigma Aldrich, Gillingham,
UK)(Mosmann, 1983). MTT was dissolved in PBS at 5 mg/ml and
ﬁltered-sterilised and then added to cells at 24 h and 48 h. Cells were in-
cubated at 37 °C for 3 h. After 3 h, the media was removed and 0.04 N
HCL-isopropanol was added to solubilise the converted formazan. Ab-
sorbance of formazan was measured at a wavelength of 570 nm with
a background absorbance of 630-690 nm. t-Tests were performed on
the MTT data using R.
3. Results
3.1. Variant identiﬁcation
Among the sixteen UCL pedigrees exome sequenced as part of the
UK10K study, the only gene in which rare (observed at a frequency of
b1% in the UK10K dataset), protein-changing variants co-segregated
with SCZ in more than one pedigree was ITGB4. One variant,
rs750367954 (C N T), had not been previously reported at the time of
analysis and was found in three affected members, two siblings and
one ﬁrst cousin, from family F158 (Fig. 1). The variant was also foundly affected families, association studies and functional analysis suggest
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tal disorder but no follow up ofmental health status was possible in this
individual. This variantwas not found in any other UK10K subjects. Two
previously reported rare variants were identiﬁed in family F047:
rs147480547 (G N A) which was shared by three affected siblings and
rs145976111 (C N T)whichwas shared by two of thembut the third sib-
ling had an unknown genotype (Fig. 1). The minor allele (A) of
rs147480547 was present in two additional UK10K SCZ subjects
(minor allele frequency (MAF) = 0.0007) while minor allele (T) of
rs145976111 was present in 7 additional UK10K SCZ subjects (MAF =
0.0025) and 3 SCOOP subjects (MAF = 0.0015).
rs750367954 C N T leads to a non-conservative amino acid change
from alanine to valine at position 1689 (A1689V) of the main isoform
of ITGΒ4 (NM_000213; Supplementary Fig. 1). The A1689V amino acid
substitution was predicted to be “Benign” with a score between 0 and
0.011 depending on the isoform by PolyPhen-2 (Supplementary
Table 2) and “Deleterious” with a score of 0.01 by SIFT (Table 1).
A1689V is present in an experimentally demonstrated protein interac-
tion domain for ERBIN (Favre et al., 2001) and in Fibronectin type III
and Immunoglobulin-like fold domains as predicted by INTERPRO
(https://www.ebi.ac.uk/interpro/protein/P16144; Supplementary
Fig. 1). rs147480547G N A causes a non-conservative amino acid change
from alanine to threonine at position 808 (A808T) of NM_000213. The
A808T amino acid substitution was predicted to be “Benign” with a
score between 0.006 and 0.335 depending on the isoform by
PolyPhen-2 and “Deleterious” with a score of 0.01 by SIFT.
rs145976111 C N T causes a non-conservative amino acid change from
arginine to cysteine at position 977 (R977C) of NM_000213 (Supple-
mentary Fig. 1). The R977C amino acid substitution was predicted to
be “Probably Damaging” with a score between 0.95 and 0.999 depend-
ing on the isoformby PolyPhen-2 (Supplementary Table 2) and “Delete-
rious” with a score of 0 by SIFT.
3.2. Association analysis
Genotype counts for the variants in the Swedish SCZ cases and con-
trols and the UCL samples are shown in Table 2. Results for the UCL SCZ
and BP cases are shown separately and combined. BP subjects were in-
cluded in the genotyping panel to allow assessment of the frequency of
variants across the psychosis spectrum. rs750367954C N Twas detected
in two Swedish cases but no other subjects and the other variants were
commoner in cases than controls in both the Swedish and UCL cohorts.
The data shows evidence for associationwith schizophrenia and bipolar
disorder separately (p = 0.0022 and p = 0.0011 respectively for
rs145976111) and for both disorders when the data was combined (p
= 0.0004 for rs145976111). Table 2 also shows the results obtained
from comparing combined genotype counts for the Swedish and UCL
cases with other subjects, both for individual variants and for a burden
test combining counts across all variants. The burden test was signiﬁ-
cant at p = 0.0000031.
3.3. Weighted burden analysis of trios
In the Bulgarian trio dataset no variants were observed at
rs147480547 G N A, rs145976111 C N T or rs750367954 C N T. However,
a gene-wise weighted burden test was carried out and providedTable 1
Prediction of variant impact on protein structure from Poly-Phen2 and SIFT for isoform 1 of ITG
Variant ID [nucleotide
change]
Amino acid
change
Poly-Phen2
rs147480547 [G/A] Ala/Thr (A808T) Benign (0.006–0.335)
rs145976111 [C/T] Arg/Cys (R977C) Probably damaging (0.95–0.99)
rs750367954 [C/T] Ala/Val (A1689V) Benign (0–0.011)
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Table 3). A QQ plot showed that the SLPs obtained closely conformed
to the null hypothesis distribution and no genewas exome-wide signif-
icant (Supplementary Fig. 2). However, out of all these genes ITGΒ4was
most highly ranked with an SLP of 4.3, corresponding to a p value of
0.00005. Table 3 shows the genotype counts for ITGΒ4 in cases and
pseudo-controls. It can be seen that the result is driven by an excess of
variants among cases at a variety of different positions (Supplementary
Fig. 1).
3.4. The impact of ITGB4 coding variants rs147480547 and rs145976111 on
SH-SY5Y cell proliferation
Quantitative PCR analysis conﬁrmed overexpression of ITGΒ4 in SH-
SY5Y cells transfected with the ITGB4 plasmid constructs compared to
SH-SY5Y cells transfected with an empty vector.
No gross morphological changes were observed in the cells
transfected with the wildtype or variant ITGB4 plasmid constructs.
Next we tested whether the variants would have an impact on SH-
SY5Y cell proliferation on the basis that Integrin β4 is thought to play
a role in neuronal survival and apoptosis signal transduction pathways
(Lv et al., 2008; Lv et al., 2006; Su et al., 2007). Cells transfected with
ITGB4 constructs containing variant alleles for both rs147480547 and
rs145976111 had increased MTT-formazan formation at both 24 and
48 h (p = 0.013 and p = 0.05 respectively) (Fig. 2). Transfection with
ITGB4 constructs expressing these variants separately produced inter-
mediate values.
4. Discussion
One approach to detect rare variants is to utilise segregation infor-
mation from multiple affected individuals within a family (Cruchaga
et al., 2014; Curtis, 2011; Timms et al., 2013). Here we describe how
exome sequencing data from related affected subjects was used to ini-
tially identify candidate variants in ITGB4. Follow up studies in other
samples provide additional support for the involvement of this gene in
the aetiology of SCZ and bipolar disorder. Further support comes from
data from 872 subjects from the Western Australian Family Study of
Schizophrenia and 36,355 controls who reported two SCZ case only
ITGB4 variants (McCarthy et al., 2017). However, it should be noted
that for rs147480547 and rs145976111 the MAF (minor allele fre-
quency) observed in both sets of controls is lower than in the Non-
Finnish European samples in the ExAC database of aggregated exome
sequencing data from large-scale sequencing projects (Lek et al.,
2016). Indeed, the ExAC allele frequencies are similar to what we ob-
serve in the cases even in the subset of samples that do not include in-
dividuals with known psychiatric diagnoses. Thus, the ﬁndings for
these variants appear to bedriven by the fact that they are unexpectedly
uncommon in the control samples. By contrast, rs750367954 is very
rare and occurs at a frequency of 0.00012 in the non-Finnish European
samples in the current version (0.3.1) of ExAC and at a frequency of
0.000025 in the non-psychiatric subjects.
ITGB4 encodes the integrin beta 4 subunit. Integrins are a large fam-
ily of heterodimeric receptors for laminin, an extracellular matrix pro-
tein which plays a fundamental role in cellular interactions, motility
and signalling during development (Tarone et al., 2000). IntegrinsΒ4 (NCBI reference sequence, NM_000213).
SIFT Likely function & domain
Deleterious (0.01) Unknown/Undeﬁned
Deleterious (0) CALX-BETA Domain
Deleterious (0.014) Protein:protein interaction with ERBIN; ﬁbronectin
type-III & immunoglobulin-like fold domains
ly affected families, association studies and functional analysis suggest
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Table 2
Genotypes of ITGΒ4 variants in the cases and controls from the Swedish schizophrenia cohort (SE); the UCL cohorts (UK); the two cohorts combined; and for a burden analysis using ge-
notypes combined across all three variants. Signiﬁcance values were obtained using Fisher's exact test. Variant positions are shown according to hg19 (GRCh37).
Variant ID (Position on Chr17) [Base pair change] Sample Genotype counts MAF P Odds ratio
AA/AB/BB (95% CI)
rs750367954 SE SCZ 2534/2/0 0.00039 0.25 Inf (0.19-Inf)
(73753036) SE control 2540/0/0 0
[C/T] UK SCZ 1275/0/0 0 NA NA
UK BP 1893/0/0 0 NA NA
UK SCZ&BP 3168/0/0 0 NA NA
UK control 1324/0/0 0 0
Combined SCZ 3802/2/0 0.0002 0.25 Inf (0.19-Inf)
Combined BP 1892/0/0 0 NA NA
Combined BP&SCZ 5694/2/0 0.00018 0.52 Inf (0.13-Inf)
Combined control 3844/0/0 0
rs147480547 SE SCZ 2532/4/0 0.00079 0.062 Inf (0.66-Inf)
(73736128) SE control 2540/0/0 0
[G/A] UK SCZ 1257/4/0 0.0016 0.21 4.16 (0.41–204.92)
UK BP 1885/6/0 0.0016 0.25 4.16 (0.50–191.48)
UK BP&SCZ 3142/10/0 0.0016 0.19 4.16 (0.59–180.66)
UK control 1310/1/0 0.0004
Combined SCZ 3789/8/0 0.0011 0.021 8.12 (1.09–359.83)
Combined BP 1885/6/0 0.0016 0.0064 12.24 (1.48–561.34)
Combined BP&SCZ 5674/14/0 0.0012 0.0069 9.49 (1.44–400.60)
Combined control 3850/1/0 0.00013
rs145976111 SE SCZ 2522/12/0 0.0024 0.021 4.02 (1.08–22.19)
(73738809) SE control 2537/3/0 0.00059
[C/T] UK SCZ 1258/10/0 0.0039 0.054 3.45 (0.89–19.53)
UK BP 1876/14/0 0.0037 0.081 3.24 (0.90–17.60)
UK SCZ&BP 3134/24/0 0.0038 0.035 3.32 (1.01–17.26)
UK control 1306/3/0 0.0011
Combined SCZ 3780/22/0 0.0029 0.0022 3.72 (1.46–11.22)
Combined BP 1876/14/0 0.0037 0.0011 4.76 (1.72–15.14)
Combined BP&SCZ 5656/36/0 0.0032 0.0004 4.07 (1.70–11.81)
Combined control 3843/6/0 0.00078
Burden analysis SCZ 11,371/32/0 0.0014 0.000038
BP 5653/20/0 0.0018 0.000015
BP&SCZ 17,024/52/0 0.0015 0.0000031
Control 11,537/7/0 0.00078
5N.L. O'Brien et al. / Schizophrenia Research xxx (2018) xxx–xxxconsist ofα and β subunits. Themain isoform of the β4 subunit consists
of 1882 amino acids. The ﬁrst 27 amino acids form a signal peptide, the
next 683 amino acids form an extracellular domain that is followed by a
short transmembrane domain. The C-terminus of the protein is an ex-
ceptionally long cytoplasmic domain of 1089 residues. The length of
the cytoplasmic domain suggests the importance of the interaction of
the β subunit with cytoplasmic proteins (Hogervorst et al., 1990;Table 3
Genotype counts for rare variants in ITGΒ4 in trio cases and pseudo-controls consisting of non-t
the excess in cases is signiﬁcant at p = 0.00005. Amino acid changes are shown for NM_00021
Position on chr17 (hg19) Variant identiﬁer, base pair and amino acid change
73724461 rs775438066 G/A; R158Q
73724543 17:73724543 G/A; M185I
73726959 17:73726959 C/T; L336F
73726989 rs778405226 G/C; G346R
73727379 rs762334700 G/A; R382Q
73728226 rs373717293 T/C;
73728300 rs8079267 G/T; Q478H
73729749 rs772615108 C/T; R545C
73736505 rs760130077 G/A; R838Q
73738731 rs764035400 C/T; R951W
73746859 17:73746859 C/G; D1191E
73746884 rs75129664 G/A; G1200R
73750828 17:73750828 G/A; R1497H
73752635 rs538467153 C/T; R1612C
73753143 rs762581242 G/A; G1725R
73753152 rs759302516 C/T; R1728C
73753278 rs200010813 C/T;
73753310 rs151327791 G/A; G1750R
73753326 rs140577812 C/T; P1755L
73753574 rs773923807 C/T; R1803W
Please cite this article as: O'Brien, N.L., et al., Rare variant analysis inmultip
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idence for interaction between the cytoplasmic domain of ITGB4 with
COL17A1, ERBIN, BP230, BP180, DST and RAC1 (Favre et al., 2001;
Hamill et al., 2009; Hopkinson and Jones, 2000; Koster et al., 2003).
Integrin β4 is found primarily in epithelial cells and binds with integrin
alpha (α) 6 (ITGA6). It is of interest that the ITGΒ4/ITGA6 complex binds
to the EGF-like domain in Neuregulin-1 (NRG1) (Ieguchi et al., 2010)ransmitted parental alleles. Using theweighted burden test implemented in SCOREASSOC,
3. NS Nonsynonymous.
Type Pseudo-controls Schizophrenia cases
AA AB BB AA AB BB
NS 589 0 0 586 3 0
NS 576 0 0 575 1 0
NS 585 0 0 584 1 0
NS 583 0 0 581 2 0
NS 534 0 0 533 1 0
Splice site 587 0 0 586 1 0
NS 586 2 0 581 7 0
NS 546 1 0 547 0 0
NS 542 0 0 541 1 0
NS 533 0 0 531 2 0
NS 576 1 0 577 0 0
NS 567 4 0 560 11 0
NS 583 0 0 582 1 0
NS 576 0 0 575 1 0
NS 535 0 0 534 1 0
NS 543 0 0 542 1 0
Splice site 532 3 0 531 4 0
NS 540 0 0 539 1 0
NS 543 1 0 543 1 0
NS 557 0 0 556 1 0
ly affected families, association studies and functional analysis suggest
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Fig. 2.MTT-formazan formation from SH-SY5Y cells overexpressing the wildtype, rs147480547, rs145976111 and both variants of the ITGΒ4 gene. The data was obtained from three
independent experiments.
6 N.L. O'Brien et al. / Schizophrenia Research xxx (2018) xxx–xxxand variants in theNRG1 genehave been previously associatedwith SCZ
(Craddock et al., 2005; Mei and Xiong, 2008). All three ITGB4 variants
identiﬁed here are located in the long cytoplasmic domain, making
them likely to have a functional impact on the interaction of integrin
β4 with other cytoplasmic proteins.
Integrin β4 is involved in cell-cell and cell-matrix adhesion. In addi-
tion to epithelial cells it is expressed in astrocytes, Schwann cells and
neurons (Jaakkola et al., 1993; Milner and Campbell, 2006; Su et al.,
2007) and it is abundantly expressed in the developing cerebral cortex
(Lv et al., 2008). Integrin β4 is important for the interaction of Schwann
cells with the basal lamina and axons, and it could inﬂuence the struc-
ture of myelinating Schwann cells (Su et al., 2008). Integrin β4 is also
believed to be a key factor in neuronal survival and apoptosis signal
transduction pathways (Lv et al., 2008; Lv et al., 2006; Su et al., 2007).
We also present in vitro evidence from our functional studies to sug-
gest that haplotypes comprising the minor alleles of rs147480547 and
rs145976111 lead to an increase in cell proliferationwith increased cel-
lular metabolic activity in human neuroblastoma cells transfected with
both variant alleles together. Integrin β4 is expressed in human neuro-
nal stem/precursor cells (Flanagan et al., 2006) and downregulation in-
hibits mouse neural stem cell differentiation (Su et al., 2008). It is well
established that the integrinβ4 andα6 complex induces c-Src signalling
and mTOR activation which is important for stimulating transcription
and translation of cancer related genes (Muranen et al., 2017; Soung
et al., 2013). Interestingly, the antipsychotic penﬂuridol has been
shown to signiﬁcantly reduce tumor growth and induce apoptosis in
cancer cell lines through inhibition of integrin signalling. This effect
was mediated by a decrease in the expression of ITGΒ4 (Ranjan et al.,
2016). Our functional studies demonstrate that ITGB4 SNP variants
rs147480547 and rs145976111 further increase cytoplasmic activityPlease cite this article as: O'Brien, N.L., et al., Rare variant analysis inmultip
a role for the ITGΒ4 gene in schizophrenia and bipolar disorder..., Schizophand cell growth in comparison with wild type ITGB4. It is thus likely
that expression of these variants in ITGB4 increase cell proliferation by
facilitating cell-cell interactions through upregulation of cell signalling.
An important limitation of this study is that our functional assays relied
on overexpression of ITGB4 in a proliferative cell line. The use of induced
pluripotent stem cells derived from patients carrying these variants
would likely provide a clearer picture of the functional effects of these
variants.
Here we report co-segregation of three rare, protein-changing vari-
ants in the ITGB4 gene with SCZ in two families, with one family pre-
senting a haplotype consisting of two of these variants. We provide
further evidence from case control cohorts of subjects that had been
exome sequenced or directly genotyped that variants in these families
may contribute to susceptibility to SCZ and/or BP in the wider popula-
tion. We also ﬁnd support for a role of the ITGB4 gene in susceptibility
to SCZ through a weighted burden test in exome data from a SCZ trio
sample and from the literature. Finally, we demonstrate that when
these variants are present on the same haplotype there is an increase
in cell proliferation in vitro.Whilst none of the results obtained provides
unequivocal evidence for the role of ITGB4 in susceptibility to psychotic
illness, considered together they are of interest and justify further inves-
tigation this gene and its variants in schizophrenia.
Supplementary data to this article can be found online at https://doi.
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